Precigen (PGEN) Free Cash Flow (2012 - 2026)
Precigen (PGEN) posted quarterly Free Cash Flow of -$44.0 million for Q1 2026, down 159.78% year-over-year from $73.6 million in Q1 2025, and down 87.52% quarter-over-quarter from -$23.5 million in Q4 2025.
Precigen (PGEN) Free Cash Flow (2012 - 2026) Analysis & Trends
Precigen (PGEN) has reported Free Cash Flow for 15 consecutive years, with -$44.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Free Cash Flow fell 159.78% year-over-year to -$44.0 million; the TTM figure through Mar 2026 stood at -$116.9 million (down 74.43% YoY), while the FY2025 annual figure was -$89.8 million, down 31.11% from the prior year.
- Free Cash Flow declined to -$44.0 million in Q1 2026 per PGEN's latest filing, from -$23.5 million in the prior quarter.
- Across five years, Free Cash Flow topped out at -$1.0 million in Q4 2024 and bottomed at -$44.0 million in Q1 2026.
- Historically, Free Cash Flow has averaged -$20.0 million across 5 years, with a median of -$18.4 million in 2024.
- Annual changes were most pronounced in 2024 — Free Cash Flow soared 93.51% — and 2025, when it plunged 2183.85%.
- Precigen's Free Cash Flow stood at -$15.4 million in 2022, then dropped by 2.54% to -$15.8 million in 2023, then jumped by 93.51% to -$1.0 million in 2024, then slumped by 2183.85% to -$23.5 million in 2025, then tumbled by 87.52% to -$44.0 million in 2026.
- Business Quant data shows PGEN's Free Cash Flow at -$44.0 million in Q1 2026, -$23.5 million in Q4 2025, and -$30.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -389.61 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 437.80 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 477.44 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 292.04 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -95.09 Mn |
| 10 | Precigen | 2.18 Bn | 2.18 Bn | 52.17 Mn | -18.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -18.20 Mn |
| Jun 30, 2026 | -18.20 Mn |
| Mar 31, 2026 | -44.03 Mn |
| Mar 31, 2026 | -44.03 Mn |
| Dec 31, 2025 | -23.48 Mn |
| Dec 31, 2025 | -23.48 Mn |
| Sep 30, 2025 | -30.79 Mn |
| Sep 30, 2025 | -30.79 Mn |
| Jun 30, 2025 | -18.61 Mn |
| Jun 30, 2025 | -18.61 Mn |
| Mar 31, 2025 | -16.95 Mn |
| Mar 31, 2025 | -16.95 Mn |
| Dec 31, 2024 | -1.03 Mn |
| Dec 31, 2024 | -1.03 Mn |
| Sep 30, 2024 | -23.62 Mn |
| Sep 30, 2024 | -23.62 Mn |
| Jun 30, 2024 | -25.43 Mn |
| Jun 30, 2024 | -25.43 Mn |
| Mar 31, 2024 | -18.44 Mn |
| Mar 31, 2024 | -18.44 Mn |